-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer is the main cause of cancer incidence and death.
sq- NSCLC s The prognosis of patients receiving standard platinum-based chemotherapy in the diagnosis of NSCLC is poor.
Tislelizumab is a monoclonal antibody with high binding affinity to the PD-1 receptor.
Recently, a study introduced the efficacy and safety results of the key phase 3 clinical trial Tislelizumab combined with chemotherapy (RATIONALE 307) for newly treated patients with advanced sq-NSCLC.
This open-label, randomized Phase 3 clinical trial was conducted in 46 locations in China from July 2018 to June 2019, including newly treated patients with histologically confirmed stage IIIB/IV sq-NSCLC.
This open-label, randomized Phase 3 clinical trial was conducted in 46 locations in China from July 2018 to June 2019, including newly treated patients with histologically confirmed stage IIIB/IV sq-NSCLC.
The patient was randomized (1:1:1) to receive the following intravenous injections with a schedule of 21 days: Tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m 2 , day 1) and carboplatin ( Areas where the concentration is lower than 5, day 1) (group a); Tislelizumab plus nab-paclitaxel (100 mg/m 2 , days 1, 8 and 15) and carboplatin (group B); paclitaxel and carboplatin (C group).
The primary endpoint is progression-free survival (PFS) as assessed by the independent review committee (IRC).
In total, 355 sq-NSCLC patients (median age, 62 years, 34-74 years; 330 men, 91.
Progression-free survival as assessed by the independent review committee
Progression-free survival as assessed by the independent review committee Progression-free survival as assessed by the independent review committee Progression-free survival as assessed by the independent review committeeIn conclusion, in this phase 3 randomized clinical trial, regardless of the expression of PD-L1, for patients with advanced sq NSCLC, the addition of Tislelizumab and IRC to chemotherapy significantly prolonged PFS, higher ORR, and better safety/resistance.
In conclusion, in this phase 3 randomized clinical trial, regardless of the expression of PD-L1, for patients with advanced sq NSCLC, the addition of Tislelizumab and IRC to chemotherapy significantly prolonged PFS, higher ORR, and better safety/resistance.
Wang J, Lu S, Yu X-, et Al Tislelizumab Plus Chemotherapy VS Chemotherapy Alone AS First-Line Treatment for Advanced Squamous Non-the Small-the Cell Lung Cancer.
:A Phase.
3 Randomized Clinical Trial :.
.
JAMA Oncol Published Online April 01, 2021.
com/journals/jamaoncology/fullarticle/2777901" target="_blank" rel="noopener">doi:10.
1001/jamaoncol.
2021.
0366com/journals/jamaoncology/fullarticle/2777901" target="_blank" rel="noopener"> doi:10.
1001/jamaoncol.
2021.
0366
leave a message here
